Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity

Nature Communications

Volumn 7, Issue , 2016, Pages

  Nguyen, Duy P ^a   Miyaoka, Yuichiro ^b,d   Gilbert, Luke A ^c   Mayerl, Steven J ^b   Lee, Brian H ^a,d   Weissman, Jonathan S ^a,c   Conklin, Bruce R ^b,c   Wells, James A ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; UNCLASSIFIED DRUG; ANTIESTROGEN; BACTERIAL PROTEIN; CAS9 ENDONUCLEASE STREPTOCOCCUS PYOGENES; CELL RECEPTOR; ENDONUCLEASE; ESTROGEN RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ALPHA; HYDROXYTAMOXIFEN; PROTEIN BINDING; TAMOXIFEN;

CHEMICAL BINDING; DESIGN; GENETIC ANALYSIS; GENETIC ENGINEERING; GENOME; LIGAND; PROTEIN;

ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; EPIGENETICS; GENE LOCUS; GENOME; LIGAND BINDING; NONHUMAN; PROTEIN DOMAIN; ANALOGS AND DERIVATIVES; CRISPR CAS SYSTEM; DRUG EFFECT; GENE EDITING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; METABOLISM; PLASMID; PROCEDURES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

BACTERIAL PROTEINS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; ENDONUCLEASES; EPIGENESIS, GENETIC; ESTROGEN ANTAGONISTS; GENE EDITING; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; PLASMIDS; PROTEIN BINDING; PROTEIN DOMAINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TAMOXIFEN;

EID: 84977106633     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12009     Document Type: Article

References (57)

1. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPRCas9 for genome engineering. Cell 157, 1262-1278 (2014).
2. Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096-1258096 (2014).
3. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
4. Jinek, M. et al. RNA-programmed genome editing in human cells. Elife 2, e00471-e00471 (2013).
5. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
6. Cho, S. W., Kim, S., Kim, J. M. & Kim, J.-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nature Biotechnol. 31, 230-232 (2013).
7. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
8. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183 (2013).
9. Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442-451 (2013).
10. Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583-588 (2015).
11. Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnol. 31, 833-838 (2013).
12. Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat. Methods 10, 973-976 (2013).
13. Maeder, M. L. et al. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10, 977-979 (2013).
14. Tanenbaum, M. E., Gilbert, L. A., Qi, L. S., Weissman, J. S. & Vale, R. D. A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159, 635-646 (2014).
15. Chavez, A. et al. Highly efficient Cas9-mediated transcriptional programming. Nat. Methods 12, 326-328 (2015).
16. Kearns, N. A. et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat. Methods 12, 401-403 (2015).
17. Hilton, I. B. et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nature Biotechnol. 33, 510-517 (2015).
18. Thakore, P. I., Black, J. B., Hilton, I. B. & Gersbach, C. A. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nature Methods 13, 127-137 (2016).
19. Gilbert, L. A. et al. Genome-Scale CRISPR-mediated control of gene repression and activation. Cell 159, 647-661 (2014).
20. Dow, L. E. et al. Inducible in vivo genome editing with CRISPR-Cas9. Nature Biotechnol. 33, 390-394 (2015).
21. Aubrey, B. J. et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep 10, 1422-1432 (2015).
22. González, F. et al. An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 15, 215-226 (2014).
23. Mandegar, M. A. et al. CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs. Cell Stem Cell 18, 1-13 (2016).
24. Zetsche, B., Volz, S. E. & Zhang, F. A split-Cas9 architecture for inducible genome editing and transcription modulation. Nature Biotechnol. 33, 139-142 (2015).
25. Nishimasu, H. et al. Crystal structure of Staphylococcus aureus Cas9. Cell 162, 1113-1126 (2015).
26. Nihongaki, Y., Kawano, F., Nakajima, T. & Sato, M. Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nature Biotechnol. 33, 755-760 (2015).
27. Davis, K. M., Pattanayak, V., Thompson, D. B., Zuris, J. A. & Liu, D. R. Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nat. Chem. Biol. 11, 316-318 (2015).
28. Wright, A. V. et al. Rational design of a split-Cas9 enzyme complex. Proc. Natl Acad. Sci. USA 112, 2984-2989 (2015).
29. Picard, D. Regulation of protein function through expression of chimaeric proteins. Curr. Opin. Biotechnol. 5, 511-515 (1994).
30. Feil, R., Wagner, J., Metzger, D. & Chambon, P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem. Biophys. Res. Commun. 237, 752-757 (1997).
31. Hameyer, D. et al. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol. Genomics 31, 32-41 (2007).
32. Esvelt, K. M. et al. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat. Methods 10, 1116-1121 (2013).
33. Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186-191 (2015).
34. Hirano, H. et al. Structure and engineering of Francisella novicida Cas9. Cell 164, 950-961 (2016).
35. Fegan, A., White, B., Carlson, J. C. T. & Wagner, C. R. Chemically controlled protein assembly: techniques and applications. Chem. Rev. 110, 3315-3336 (2010).
36. Chylinski, K., Le Rhun, A. & Charpentier, E. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol. 10, 726-737 (2013).
37. Nishimasu, H. et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935-949 (2014).
38. Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759-771 (2015).
39. Miyaoka, Y. et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods 11, 291-293 (2014).
40. Köhler, A. & Hurt, E. Exporting RNA from the nucleus to the cytoplasm. Nat. Rev. Mol. Cell Biol. 8, 761-773 (2007).
41. Sauvez, F., Drouin, D. S., Attia, M., Bertheux, H. & Forster, R. Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats. Carcinogenesis 20, 843-850 (1999).
42. García-Otín, A. L. & Guillou, F. Mammalian genome targeting using site-specific recombinases. Front. Biosci. 11, 1108-1136 (2006).
43. Kotterman, M. A. & Schaffer, D. V. Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 15, 445-451 (2014).
44. Fine, E. J. et al. Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes. Sci. Rep 5, 10777 (2015).
45. Truong, D.-J. J. et al. Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res. 43, 6450-6458 (2015).
46. Day, T. P., Byrne, L. C., Schaffer, D. V. & Flannery, J. G. Advances in AAV vector development for gene therapy in the retina. Adv. Exp. Med. Biol. 801, 687-693 (2014).
47. McCarty, D. M. Self-complementary AAV vectors; advances and applications. Mol. Ther. 16, 1648-1656 (2008).
48. Betley, J. N. & Sternson, S. M. Adeno-associated viral vectors for mapping, monitoring, and manipulating neural circuits. Hum. Gene Ther. 22, 669-677 (2011).
49. Biggins, J. B. & Koh, J. T. Chemical biology of steroid and nuclear hormone receptors. Curr. Opin. Chem. Biol. 11, 99-110 (2007).
50. Gallinari, P. et al. A functionally orthogonal estrogen receptor-based transcription switch specifically induced by a nonsteroid synthetic ligand. Chem. Biol. 12, 883-893 (2005).
51. Hassan, A. Q. & Koh, J. T. A functionally orthogonal ligand-receptor pair created by targeting the allosteric mechanism of the thyroid hormone receptor. J. Am. Chem. Soc. 128, 8868-8874 (2006).
52. Bain, D. L., Heneghan, A. F., Connaghan-Jones, K. D. & Miura, M. T. Nuclear receptor structure: implications for function. Annu. Rev. Physiol. 69, 201-220 (2007).
53. Fahrbach, S. E., Smagghe, G. & Velarde, R. A. Insect nuclear receptors. Annu. Rev. Entomol. 57, 83-106 (2012).
54. Hathaway, N. A. et al. Dynamics and memory of heterochromatin in living cells. Cell 149, 1447-1460 (2012).
55. Gray, D. C., Mahrus, S. & Wells, J. A. Activation of specific apoptotic caspases with an engineered small-molecule-activated protease. Cell 142, 637-646 (2010).
56. Nguyen, D. P. et al. Genetic encoding of photocaged cysteine allows photoactivation of TEV protease in live mammalian cells. J. Am. Chem. Soc. 136, 2240-2243 (2014).
57. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).